GlobalData on MSN5d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce ...
In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
In another cautionary tale of kicking all the tires before an acquisition, Pfizer Inc. agreed to a nearly $60 million settlement to resolve a whistleblower’s claims that Biohaven Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback